Department of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), 28040 Madrid, Spain.
Viruses. 2018 Aug 24;10(9):453. doi: 10.3390/v10090453.
Zika virus (ZIKV), a mosquito-borne flavivirus, was an almost neglected pathogen until its introduction in the Americas in 2015, where it has been responsible for a threat to global health, causing a great social and sanitary alarm due to its increased virulence, rapid spread, and an association with severe neurological and ophthalmological complications. Currently, no specific antiviral therapy against ZIKV is available, and treatments are palliative and mainly directed toward the relief of symptoms, such as fever and rash, by administering antipyretics, anti-histamines, and fluids for dehydration. Nevertheless, lately, search for antivirals has been a major aim in ZIKV investigations. To do so, screening of libraries from different sources, testing of natural compounds, and repurposing of drugs with known antiviral activity have allowed the identification of several antiviral candidates directed to both viral (structural proteins and enzymes) and cellular elements. Here, we present an updated review of current knowledge about anti-ZIKV strategies, focusing on host-directed antivirals as a realistic alternative to combat ZIKV infection.
寨卡病毒（ZIKV）是一种蚊媒黄病毒，直到 2015 年在美洲被发现，它才成为一种被忽视的病原体，在美洲，寨卡病毒的毒力增加、传播迅速，并与严重的神经和眼科并发症有关，这对全球健康构成了威胁，引起了极大的社会和公共卫生警报。目前，尚无针对寨卡病毒的特效抗病毒疗法，治疗方法是姑息性的，主要通过解热、抗组胺和补液治疗来缓解发热和皮疹等症状。然而，最近，对抗病毒药物的研究已成为寨卡病毒研究的主要目标。为此，对来自不同来源的文库进行筛选、测试天然化合物以及重新利用具有已知抗病毒活性的药物，已经确定了几种针对病毒（结构蛋白和酶）和细胞成分的抗病毒候选药物。在这里，我们对目前关于抗寨卡病毒策略的知识进行了更新，重点介绍了宿主定向抗病毒药物作为对抗寨卡病毒感染的一种现实替代方法。
